CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a Healthcare company (Biotechnology) with a market capitalization of $423M. The Maz Rating grades it against the other companies in its sector.
CytomX Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.94, CytomX Therapeutics, Inc. trades at 30.0x sales and 1.5x book value. Over the last twelve months it generated about $14M of revenue and a net loss of $99M. It runs a gross margin of 98.2%, an operating margin of -676.5% and a net margin of -609.0%. It shows return on equity of -34.0%, return on invested capital of -29.7% and a free cash flow yield of -12.1%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 7.82. Over the past 52 weeks the share price ranged from $1.90 to $8.21, with a beta of 2.24.
CytomX Therapeutics, Inc. does not currently pay a dividend.
21 Wall Street analyst ratings cover the stock: 17 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, CytomX Therapeutics, Inc. (CTMX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 58.2% / 30% · Interest income / Revenue 193.8% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 58.2% / 33% · Receivables / Mkt Cap (36m) 0.08% / 49% · Interest income / Revenue 193.8% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 58.2% / 33.33% · Receivables / Mkt Cap (24m) 0.08% / 33.33% · Interest income / Revenue 193.8% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.68% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 92.5% / 33.33% · Receivables / Avg Assets (4Q) 3.23% / 33.33% · Interest income / Revenue 193.8% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 95.4% / 33.33% · (Cash+Recv) / Total Assets 95.6% / 33.33% · Interest income / Revenue 193.8% / 5% | Fail |
No. As of September 2026, CytomX Therapeutics, Inc. (CTMX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. CytomX Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 193.8% of each dividend: CytomX Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.